Home > Insider Trading > Filing (0001415889-25-000220)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817229	Vor Biopharma Inc.	VOR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1519339	Reid Hoffman	101 Mission Street, Suite 1000 San Francisco CA 94105		No	No	Yes	No
2050755	Reprogrammed Interchange Llc	101 Mission Street, Suite 1000 San Francisco CA 94105		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-12-30	38,974,101	$0.00	38,974,101	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant (Right to Buy)	Acquisiton	2024-12-30	48,717,626	$0.00	48,717,626	$0.84

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
48,717,626		2031-12-30	No	4	P	Direct

Footnotes

Each share of Common Stock was purchased together with an accompanying Warrant to purchase 1.25 shares of Common Stock. The purchase price of the securities was $0.99425 per share and accompanying Warrant.
The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
The Warrants are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Warrants to the extent that such exercise would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.